Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

critical-insights-from-alignment-healthcare-analyst-ratings:-what-you-need-to-know

Critical Insights From Alignment Healthcare Analyst Ratings: What You Need To Know

Jul 26, 2024

In the latest quarter, 4 analysts provided ratings for Alignment Healthcare ALHC, showcasing a mix of bullish and…

Read more
dexcom-faces-short-term-challenges,-but-market-growth-prospects-remain-strong:-analyst

DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong: Analyst

Jul 26, 2024

DexCom Inc DXCM reported second-quarter sales of more than $1 billion. That’s up 15% year-over-year on a reported…

Read more
usana-health-sciences,-inc.-earnings-missed-analyst-estimates:-here’s-what-analysts-are-forecasting-now

USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here’s What Analysts Are Forecasting Now

Jul 26, 2024

As you might know, USANA Health Sciences, Inc. (NYSE:USNA) last week released its latest second-quarter, and things did…

Read more
analyst-ratings-for-idexx-laboratories

Analyst Ratings For IDEXX Laboratories

Jul 26, 2024

In the latest quarter, 4 analysts provided ratings for IDEXX Laboratories (NASDAQ:IDXX), showcasing a mix of bullish and…

Read more
cara-therapeutics-(nasdaq:cara)-research-coverage-started-at-stocknews.com

Cara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.com

Jul 25, 2024

Posted by Defense World Staff on Jul 24th, 2024 Stock analysts at StockNews.com started coverage on shares of…

Read more
demystifying-steven-madden:-insights-from-4-analyst-reviews

Demystifying Steven Madden: Insights From 4 Analyst Reviews

Jul 25, 2024

4 analysts have expressed a variety of opinions on Steven Madden (NASDAQ:SHOO) over the past quarter, offering a…

Read more
brooklyn-immunotherapeutics-(nyse:btx)-coverage-initiated-by-analysts-at-stocknews.com

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Jul 25, 2024

Equities research analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in…

Read more
cellectis-(nasdaq:clls)-research-coverage-started-at-stocknews.com

Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

Jul 25, 2024

Posted by Defense World Staff on Jul 24th, 2024 Stock analysts at StockNews.com assumed coverage on shares of…

Read more
earnings-beat:-galp-energia,-sgps,-sa.-just-beat-analyst-forecasts,-and-analysts-have-been-updating-their-models

Earnings Beat: Galp Energia, SGPS, S.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 25, 2024

Galp Energia, SGPS, S.A. (ELI:GALP) just released its quarterly report and things are looking bullish. It was a…

Read more
lockheed-martin-shares-climb-on-positive-analyst-ratings-and-strong-q2-results

Lockheed Martin Shares Climb On Positive Analyst Ratings And Strong Q2 Results

Jul 25, 2024

Lockheed Martin Corporation (NYSE:LMT) shares are higher Wednesday after multiple analysts raised their price targets following the company’s…

Read more
rbc-capital-launches-coverage-on-compass-pathways,-cites-$2.3b-revenue-potential

RBC Capital launches coverage on Compass Pathways, cites $2.3B revenue potential

Jul 24, 2024

The analyst sees “attractive” opportunity in CMPS beyond depression, with promising early data in post-traumatic stress disorder. RBC…

Read more
a-closer-look-at-5-analyst-recommendations-for-signet-jewelers

A Closer Look at 5 Analyst Recommendations For Signet Jewelers

Jul 24, 2024

Ratings for Signet Jewelers (NYSE:SIG) were provided by 5 analysts in the past three months, showcasing a mix…

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 363
  6. 364
  7. 365
  8. 366
  9. 367
  10. 368
  11. 369
  12. ...
  13. 447
  14. »

Posts pagination

Newer posts Page 1 … Page 366 … Page 447 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.